Trevi Therapeutics Inc (TRVI) Stock Price, Quote & News

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 304 2499

Website: www.trevitherapeutics.com

Address:

195 Church Street, 16th Floor, New Haven, United States

ZR92x Aug. 29 at 2:12 PM

$TRVI On July 8th (1 month ago), the CFO did an interview where she says in the interview at 11:04 "a big priority for me right now is getting the company ready to be SOX-404(b) compliant which is a significant exercise for a smaller company". . Which begs the question - why would she leave the company 1 month later in the middle of such a large undertaking that she said was her priority last month? Maybe they are getting acquired so they don't need to worry about becoming SOX-404(b) compliant anymore 11:04 https://www.youtube.com/watch?v=Hyc2ChelduM

1 · Reply

Zooooo Aug. 29 at 1:27 PM

$TRVI All I know is somebody bought $7 $1.3 sweepers that won't break even until $8.3 so if its a bullish bet they think it goes over $8.3 or if it's a hedge of a bearish bet they think it's going under $5.7 by Sept 19.

0 · Reply

nUmP_08Glare Aug. 29 at 12:34 PM

$TRVI UTRX watch for that first PR confirming monthly BTC receipts then the rerate starts chart fireworks potential if volume arrives together with news 🎇

0 · Reply

ZR92x Aug. 29 at 12:07 PM

$TRVI Some professional background for CFO Rachel Delfini - “Her background includes helping public and private companies with finance transformation and preparing for and executing capital raising activities, acquisitions, and other complex financial and accounting matters. As a Financial Accounting and Advisory Services Partner at Marcum LLP, Ms. Delfini led a team of professionals who provided advisory services on financial activities to companies. In this role, she served as interim CFO, CAO or controller for companies in multiple sectors, including pharmaceuticals” - it seems that she has a history of brief tenures at companies serving as interim/fractional CFO - offering advisory services for companies to help them with whatever their goals are (including acquisitions)

2 · Reply

Zooooo Aug. 29 at 11:56 AM

$TRVI What I do know is the CFO gave 1 weeks notice of resignation on Aug 14, resigned Aug 22nd, elected to sell all her shares on Aug 27 (stock rallied hard this day) and then stock tanked Aug 28. CFO leaving a pre-revenue company with cash to 2029 isn't really bullish or bearish. Some think it's related to a potential acquisition <--- CFO role of acquired biotech company usually gets cut. I was guessing the volatility was tied to speculation that conferences got cancelled, and then they announced they would partake in all the conferences yesterday.

1 · Reply

Zooooo Aug. 29 at 11:51 AM

$TRVI lol open interest increased. This is a total clown show and I have no idea what is going on.

0 · Reply

ZR92x Aug. 29 at 11:50 AM

$TRVI Open interest for the September $7 calls WENT UP despite the sell-off!!! They are still holding and adding more on the dip!! Yesterday - 15,591 This morning - 15,978 (+387) Volume was over 1,500 but the net gain was +387

0 · Reply

Warrock Aug. 29 at 1:11 AM

$TRVI All the $7 call were closed before the market closed. It was clearly a pump and dump to unload shares, and all the $7 call options were just a decoy.

1 · Reply

Richapeslayer_pounce Aug. 28 at 8:50 PM

$TRVI $20 stock trading at $7 buy it while you can

0 · Reply

drewboca Aug. 28 at 8:03 PM

$TRVI just weird

1 · Reply

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 8, 2025, 1:47 PM EDT - 23 days ago

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 24 days ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 4:05 PM EDT - 4 weeks ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 4 weeks ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 1, 2025, 7:30 AM EDT - 2 months ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 5, 2025, 4:30 PM EDT - 3 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 3, 2025, 10:15 PM EDT - 3 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 2, 2025, 4:01 PM EDT - 3 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Jun 2, 2025, 1:42 PM EDT - 3 months ago

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Jun 2, 2025, 7:00 AM EDT - 3 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 3 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 29, 2025, 7:30 AM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

$Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

May 20, 2025, 7:00 AM EDT - 3 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 11, 2025, 4:16 AM EDT - 4 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 4 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 1, 2025, 4:05 PM EDT - 4 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Apr 3, 2025, 7:30 AM EDT - 5 months ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Mar 18, 2025, 6:47 PM EDT - 5 months ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 5 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 11, 2025, 4:05 PM EDT - 6 months ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 10, 2025, 11:30 AM EDT - 6 months ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 10, 2025, 6:00 AM EDT - 6 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 9, 2025, 4:00 PM EDT - 6 months ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Feb 27, 2025, 7:30 AM EST - 6 months ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 6 months ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Jan 30, 2025, 7:30 AM EST - 7 months ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 8, 2025, 7:30 AM EST - 8 months ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:36 AM EST - 9 months ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 12, 2024, 9:47 AM EST - 9 months ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 7:30 AM EST - 9 months ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 3, 2024, 4:05 PM EST - 9 months ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Nov 21, 2024, 7:30 AM EST - 10 months ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 11:54 PM EST - 10 months ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 10 months ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 30, 2024, 4:05 PM EDT - 10 months ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

$Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough$

Oct 21, 2024, 7:30 AM EDT - 11 months ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Oct 15, 2024, 7:30 AM EDT - 11 months ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Oct 3, 2024, 4:05 PM EDT - 11 months ago

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Sep 30, 2024, 5:30 PM EDT - 11 months ago

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Aug 28, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Aug 11, 2024, 1:28 AM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

May 11, 2024, 1:56 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming Conferences

ZR92x Aug. 29 at 2:12 PM

1 · Reply

Zooooo Aug. 29 at 1:27 PM

0 · Reply

nUmP_08Glare Aug. 29 at 12:34 PM

$TRVI UTRX watch for that first PR confirming monthly BTC receipts then the rerate starts chart fireworks potential if volume arrives together with news 🎇

0 · Reply

ZR92x Aug. 29 at 12:07 PM

2 · Reply

Zooooo Aug. 29 at 11:56 AM

1 · Reply

Zooooo Aug. 29 at 11:51 AM

$TRVI lol open interest increased. This is a total clown show and I have no idea what is going on.

0 · Reply

ZR92x Aug. 29 at 11:50 AM

0 · Reply

Warrock Aug. 29 at 1:11 AM

$TRVI All the $7 call were closed before the market closed. It was clearly a pump and dump to unload shares, and all the $7 call options were just a decoy.

1 · Reply

Richapeslayer_pounce Aug. 28 at 8:50 PM

$TRVI $20 stock trading at $7 buy it while you can

0 · Reply

drewboca Aug. 28 at 8:03 PM

$TRVI just weird

1 · Reply

Richapeslayer_pounce Aug. 28 at 4:41 PM

$TRVI Back at support buy and repeat right here

0 · Reply

ZR92x Aug. 28 at 3:39 PM

$TRVI That is conviction.. Maybe there truly was a buyout leak if they are diamond hands-ing their absurdly huge call options. Balls of steel.

1 · Reply

ZR92x Aug. 28 at 3:37 PM

$TRVI They are still holding their options despite losing probably $500,000 or more on them today with the retracing of the gap up. I think they paid at least $1.25-$1.50 average (maybe even more) for them. Now they are $0.95

0 · Reply

drewboca Aug. 28 at 3:01 PM

$TRVI FYI. Your allowed to Short stock against your options

0 · Reply

peapope Aug. 28 at 2:58 PM

$TRVI crazy pump and dump

0 · Reply

Zooooo Aug. 28 at 2:37 PM

$TRVI Turns out that options buyer was just a moron oh well

1 · Reply

ZR92x Aug. 28 at 12:35 PM

$TRVI Open Interest for September $7 calls is over 15,000 today. Looks like they are still holding them today after yesterdays huge buys… WOW!!!!

0 · Reply

Zooooo Aug. 28 at 2:03 AM

$TRVI I love that nobody gives a shit about this stock and its outperformed almost all the consensus garbage biotech longs

1 · Reply

peapope Aug. 27 at 10:39 PM

$TRVI quick question for this board…why does CFO leave before buyout? Why not wait for news and stock/options increase and on top of a successful acquisition? Seems premature, unless he is already on to the next gig? Not a bear just askin thx in advance realize this company has great biotech IP

1 · Reply

abcdzepeda Aug. 27 at 7:58 PM

$TRVI Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharma focused on treatments for cough conditions, traded higher on Wednesday after B. Riley, with a Buy rating, reportedly highlighted the company’s deal prospects following the recent departure of its CFO. “We are going to a nice post-Labor Day period toward the end of the year where deals should happen, and with the CFO departure, people can read it however they want,” analyst Mayank Mamtani said in an interview, according to Bloomberg News

0 · Reply

ZR92x Aug. 27 at 7:36 PM

$TRVI A 12,400% surge in a call option over a single day indicates a massive, abnormal spike in bullish options trading, primarily driven by market-moving events rather than typical trading activity. For a surge of this magnitude, the most likely culprits are a short squeeze coordinated by retail traders or the emergence of a meme stock. A surge of this magnitude is a black swan event, not standard market behavior It is a sign of intense, speculative, and often coordinated activity, not typical institutional trading. It highlights the potential for volatility when factors like social media, retail trading, and market leverage combine A sudden takeover bid or merger announcement could lead to a massive, speculative surge in call options as traders bet on a higher stock price

1 · Reply

Zooooo Aug. 27 at 6:54 PM

$TRVI @RonIsWrong SOS here... They bought 7.5k options this morning. Another 7.5k print recently --- is that buy or sell volume?

1 · Reply

Market Cap	883.49M
Revenue (ttm)	0.00
Net Income (ttm)	-47.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,556,800
Avg Vol	1,844,634
Day's Range	N/A - N/A
Shares Out	121.78M
Stochastic %K	10%
Beta	0.71
Analysts	Strong Sell
Price Target	$20.36